Vertex Pharmaceuticals (NASDAQ: VRTX) boasts an impressive track record, establishing itself as a leading biotech firm over the last decade. The company has demonstrated a keen emphasis on addressing a specific rare lung disease, cystic fibrosis (CF).
Despite facing no direct competition in this niche, Vertex has strategically chosen to broaden its portfolio by introducing therapies in additional medical domains.
The company discovered, developed and produced the first medicines to target the underlying cause of CF — the result of more than 20 years of research and development. Vertex’s dominance in CF has led to excellent financial results for the past decade.
Picks for you
Vertex also boasts several exciting candidates outside of its core CF area. One of its promising early-stage products is VX-880, a potential functional cure for type 1 diabetes. Furthermore, it accomplished this goal with Casgevy, a gene-editing treatment for two rare blood disorders: transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD).
Casgevy, which Vertex developed with CRISPR Therapeutics, just earned the green light in the UK; the evidence suggests that more regulatory approvals in the US are forthcoming. If the medicine receives approval in the US, it will further push the price of the stock.
As Vertex continues to broaden its array of approved therapies, the prospects for the company and its shareholders are anticipated to improve even further. Despite consistently delivering market-beating returns in recent times, it is by no means too late to consider investing in Vertex, as it’s currently trading at 343.05.
Analysts predictions
A synthesis of projections from 21 analysts on TipRanks over the previous quarter indicates a 12-month average price target of $390.26 for Vertex Pharmaceuticals.
This suggests a potential increase of 10.5% from its current price of 343.05 and a ‘Moderate Buy’ recommendation. Based on the last three months’ rating, INTC has received 15 ‘Buy’ ratings, 6 ‘Hold’ ratings, and notably 0 ‘Sell’ rating.
The stock’s price targets exhibit a range, spanning from a high of $456 to a low of $325.
Based on the analysis, dollar-cost averaging (DCA) might be a prudent strategy for investing in this stock.
The absence of a Sell rating suggests a long-term potential for the stock. However, the moderate buy rating may indicate that the stock is currently overbought.
In such cases, investors could consider DCA and buying during market dips, allowing them to accumulate shares over time at more favorable prices. This approach may allow building a position in the stock gradually and at a reasonable average cost.
Buy stocks now with Interactive Brokers – the most advanced investment platform
Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
